Valneva Announces the Availability of Documentation for its Shareholder Meetings
02 Juin 2022 - 08:50PM
Valneva Announces the Availability of Documentation for its
Shareholder Meetings
Saint Herblain
(France), June
2, 2022
– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty
vaccine company, today announced the availability of documentation
for its Combined General Meeting and Special Meeting of holders of
Convertible Preferred Shares.
The Company’s Combined General Meeting will be
held on June 23, 2022, at 2 p.m. CEST, at the Hotel
InterContinental Paris Le Grand, 2 rue Scribe, 75009 Paris, and
will follow a Special Meeting of holders of Convertible Preferred
Shares1 to be held at the same location at 1:30 p.m. CEST on the
same day.
The preliminary Notices of Meetings, containing
the agenda, the draft resolutions and instructions for
participation and voting, were published in the French Bulletin des
Annonces Légales Obligatoires (BALO) on May 18, 2022.
Documents and information relating to the
Meetings are available on Valneva’s website (www.valneva.com) in
the “Investors/General Meetings” section. Shareholders can also
obtain the Combined General Meeting and Special Meeting documents
upon request to the Company by sending an email to the following
address: assemblee.generale@valneva.com.
The Company also recommends that shareholders
regularly consult the sections related to the the Combined General
Meeting and Special Meeting on its website, www.valneva.com.
Contact
Details,
Legal
DepartmentValneva SEService
Assemblée Générale6 rue Alain Bombard, 44800 Saint-Herblain
(France)assemblee.generale@valneva.com
Media
& Investor ContactsLaëtitia Bachelot-FontaineVP Global
Communications & European Investor RelationsM +33 (0)6 4516
7099
laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
About Valneva SEValneva is a
specialty vaccine company focused on the development and
commercialization of prophylactic vaccines for infectious diseases
with significant unmet medical need. The Company takes a highly
specialized and targeted approach to vaccine development and then
applies its deep understanding of vaccine science to develop
prophylactic vaccines addressing these diseases. Valneva has
leveraged its expertise and capabilities both to successfully
commercialize two vaccines and to rapidly advance a broad range of
vaccine candidates into and through the clinic, including
candidates against Lyme disease, the chikungunya virus and
COVID-19.
1 Convertible Preferred Shares are special instruments created
in 2015 and held by Senior Management.
- 2022_06_02_VLA_AGM_Documentation_PR_EN_Final
Valneva (EU:VLA)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Valneva (EU:VLA)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024